Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.
Mentors in Medicine Series on Applied Precision Medicine: Focus on Where We Are in Melanoma After 10 Years With Immunotherapy
Release Date: July 1, 2021
Expiration Date: July 1, 2022
Activity Overview
Mentors in Medicine Series on Applied Precision Medicine: Focus on Where We Are in Melanoma After 10 Years With Immunotherapy is a CME-certified, case-based, live webcast. This educational activity will provide practicing oncologists with expert perspectives on incorporating biomarker testing into everyday clinical practice to determine diagnosis and inform treatment selection for their patients with melanoma. Renowned faculty will analyze recent clinical trial evidence to optimize therapeutic strategies, using real patient cases as a starting point. Each case will include an expert analysis of Show Me the Data® as well as Key Takeaways 4 Tomorrow that can be applied immediately in the oncology clinical practice.
This educational activity is an archive of the live virtual webcast held on June 24, 2021.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is intended for medical oncologists involved in the treatment of patients with melanoma. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate biomarker testing into diagnosis and/or therapy selection for treatment of patients with melanoma
- Analyze recent data on the efficacy and safety of therapeutic options for the treatment of patients with melanoma
- Apply optimal management strategies in the treatment of patients with melanoma based on recent clinical trial findings
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Series Chair
Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack Meridian School of Medicine
Professor of Medicine – Georgetown University
Hackensack, NJ
Disclosures: Grant/Research Support: PI: Acerta Pharma, AstraZeneca, Celgene Corporation, Constellation Pharmaceuticals, Genentech/Hoffmann-La Roche, Infinity Pharmaceuticals, Infinity Pharmaceuticals/Verastem Oncology, Janssen Pharmaceuticals, Karyopharm Therapeutics, Kite Pharma, Pharmacyclics; Consultant: Acerta Pharma, Celgene Corporation, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma, Xcenda; Stock/Shareholder: COTA Healthcare; Other: Honoraria: AstraZeneca, Celgene Corporation, Gilead Sciences, Kite Pharma, Xcenda; Advisory: AstraZeneca, COTA Healthcare, Elsevier’s PracticeUpdate, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma.
Moderator
President, Physician Enterprise
Chief Innovation Officer
Professor and Vice President of Cancer Services
John Theurer Cancer Center
Hackensack Meridian Health
Hackensack, NJ
Disclosures: Speakers’ Bureau: Bristol Myers Squibb.
Faculty
Assistant Attending Physician
Melanoma Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Daichii Sankyo; Consultant: Iovance Biotherapeutics, Novartis Pharmaceutical Corporation, Nanobiotix, Jo’Ann Medical Shanghai; Other Support: Speaking Honorarium: LG Chem Life Sciences.
Assistant Professor
Department of Radiation Oncology
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, CA
Disclosures: Grant/Research Support: Highlight Therapeutics, Inc.; Stock/Shareholder: Certis Oncology, T Cure Bioscience.
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Melanoma Disease Center
Director, Clinical Sciences
Center for Immuno-Oncology
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Dr Patrick Ott has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
